{"entity":{"id":"nct03839524","kind":"trial","name":"A Trial Evaluating TG4050 in Ovarian Carcinoma.","aka":[],"tldr":"A phase 1 trial of TG4050 run by Transgene, completed.","summary":"A Trial Evaluating TG4050 in Ovarian Carcinoma. is a phase 1 interventional study registered as NCT03839524 by Transgene, with 64 participants enrolled, started 2019-12-09. Conditions recorded: Ovarian Carcinoma, Fallopian Tube Cancer and Peritoneal Carcinoma. Interventions recorded: TG4050.","status":"completed","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT03839524","url":"https://clinicaltrials.gov/study/NCT03839524"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":["tg4050"],"companies":["transgene"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03839524","phase":"1","setting":"A Phase I Trial Evaluating a Mutanome-directed Immunotherapy in Patients With High Grade Serous Carcinoma (HGSC) of the Ovary, Fallopian Tube or Peritoneum.","sponsor":"Transgene","enrolled":64,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03839524/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"drug":[{"id":"tg4050","kind":"drug","name":"TG4050","route":"/drugs/tg4050/"}],"company":[{"id":"transgene","kind":"company","name":"Transgene","route":"/companies/transgene/"}]}}